Opening the Nottingham office brings PDS closer together with the Biotech community, allowing the company to better serve its clients with outsourced Pharmacovigilance services for Clinical Trials. In recent years this has become a key area of growth and so being more accessible to the Biotech community is a logical step. In addition, PDS will be holding a range of events and seminars at the Nottingham site, whilst also creating a world class, state-of-the-art facility for hosting clients and partners.
Looking forward, PDS aims to build on and strengthen its existing partnerships within the Biotech community and to develop new ones. BioCity is very much a hub for innovation, which will undoubtedly foster sustainable growth and development for partner companies within the network. Additionally, established links with the Biotech communities in the north of England and Scotland, provides a strong network of life-science companies driving innovation throughout the UK.
Whilst PDS would never lay claim to being innovative by comparison, it does support this innovation through its vast experience and knowledge of PV in Clinical Trials. Acting as a key drug safety partner, PDS helps Biotech companies remain compliant throughout the clinical development phase, provides invaluable support towards gaining approval to market a product and in post market surveillance.
Finally, a boasted 91% survival rate of companies based at BioCity in Nottingham demonstrates the tangible benefits of being located within the BioCity network. As a respected provider of pharmacovigilance and regulatory services, PDS is in a position to help sustain such high success rates through providing practicable advice and professional services to the Biotech community.
Carol Kingstone, Managing Director at PDS commented, “These are hugely exciting times for PDS and we are delighted to be in a position to work more closely with the Biotech community through providing critical pharmacovigilance and regulatory services to support its growth.
‘With our TEAM focused, partnership approach, we look forward to developing high value and mutually beneficial relationships in the coming years, and to contributing to the success of the UK Biotech industry.’
For further information about PDS please visit puredrugsafety.com.